Best Practices and Research Advances in Thoracic Oncology: A Regional Series Eastern Europe/Baltic Course 3: Driver Alterations in Lung Cancer-Targeted Therapies in Advanced Disease

Video Transcription

Video Summary

Dr. Magdalena Knietki-Wroblewska presented an overview of targeted therapies in advanced non-small-cell lung cancer (NSCLC), emphasizing molecular abnormalities and the differences observed between white and Asian populations, as well as smokers and non-smokers. Key targets in such therapies include EGFR, ALK, and KRAS, with distinct characteristics and prevalence across demographics. EGFR mutations, for instance, are often seen in non-smokers and can significantly benefit from osimertinib, which has improved progression-free survival rates notably. Meanwhile, ALK inhibitors, like lorlatinib, show significant intracranial activity beneficial for patients with brain metastases. The presentation also highlighted the importance of NGS (next-generation sequencing) for identifying oncogenic alterations, advocating its use for all advanced non-squamous NSCLC cases. Moreover, emerging treatments such as amivantamab and larotrectinib were discussed for their promising results but also presented challenges in safety profiles. Dr. Knietki-Wroblewska emphasized keeping updated with evolving treatment guidelines for optimal patient care.

Asset Subtitle

Magdalena Knetki - Wróblewska, MD, PhD

Keywords

NSCLC

targeted therapies

EGFR mutations

ALK inhibitors

next-generation sequencing

emerging treatments